Fast Growing Furious Races for Targeting Fibroblast Growth Factor Receptors

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Targeting fibroblast growth factor receptors (FGFRs) has lagged behind other receptor tyrosine kinase inhibitors in cancer therapy.
• Low efficacy and variable responses have hindered the clinical development of FGFR inhibitors.
• Fibroblast growth factor receptors are implicated in various cancers, making them a target of interest.

Purpose of the Study:

• To review the challenges and recent advancements in targeting fibroblast growth factor receptors (FGFRs) in cancer therapy.
• To highlight the role of systematic and genomic approaches in identifying conditions for effective FGFR targeting.
• To discuss the ongoing development of novel FGFR inhibitors in clinical and preclinical trials.

Main Methods:

• Review of existing literature on FGFR inhibitors and targeted cancer therapies.
• Analysis of recent systematic and genomic studies identifying FGFR-targeting strategies.
• Examination of data from ongoing clinical and preclinical trials of FGFR inhibitors.

Main Results:

• FGFR inhibitor development has been slower than other targeted therapies due to efficacy and response variability.
• Systematic and genomic approaches are revealing specific biological contexts for effective FGFR targeting.
• Numerous FGFR inhibitors are progressing rapidly through clinical and preclinical development.

Conclusions:

• Despite past challenges, FGFRs are becoming increasingly targetable with more precise and effective drugs.
• Advancements in understanding FGFR biology are crucial for overcoming previous limitations.
• The ongoing race in developing FGFR inhibitors promises improved targeted cancer therapies.